David Bruce, identified Brucella melitensis in 1886, initially known as Malta Fever. Themistocles Zammit later revealed its zoonotic origin in goats. Brucella is a zoonotic disease transmitted from animals to humans. Brucella is a non-spore-forming gram-negative coccobacilli, lack capsules and virulence genes. Despite being non-motile, they possess genes for flagellum construction. The Brucella genus comprised of nine species shows host-specific genomic similarities, challenging understanding of survival mechanisms and intracellular growth. In animals, Brucella enters via mucous membranes or skin, bypassing immune defenses in organs, causing persistent infections, especially in the reproductive tract, leading to abortion. Infected animals shed the bacteria in fluids. In humans, Brucellosis enters through contaminated products or direct contact with animals, inducing systemic symptoms. Chronic cases may result in skeletal issues or rare neurological complications. Brucellosis, a geographically dynamic disease, in which cases are prevalent in Central Asia and escalating across the Middle East. Despite successful eradication in certain regions, brucellosis persists globally, impacting animal production and public health. Brucella strains exhibit zoonotic potential, with B. melitensis posing the highest risk. Effective eradication efforts have reduced human cases in certain countries. Human brucellosis presents diagnostic challenges, relying on laboratory tests due to varied clinical manifestations. Culture isolation remains the gold standard, while serological tests like the Brucella agglutination test and PCR-based methods are essential. In cattle, the Brucella ring test and blood tests are key for monitoring and eradication efforts. Swine brucellosis lacks a reliable serological test, but buffered plate Brucella antigen tests are practical. Ovine and caprine brucellosis screening relies on tests like the Rose Bengal plate agglutination, complement fixation, and indirect ELISA tests. Brucellosis treatment challenges arise from intracellular adaptation of the bacteria. Combining doxycycline and streptomycin (DS) is the most effective, although parenteral administration poses challenges. The rifampicin-doxycycline (DR) oral regimen is an alternative, but less potent, requiring individualized consideration, monitoring, and follow-up for optimal outcomes. In highprevalence areas, controlling and eradicating brucellosis involves vaccination and the removal of infected animals. Key vaccines include B. abortus strains 19 and RB51 for cattle and B. melitensis strain Rev1 for goats and sheep. Despite vaccination, total Brucella eradication requires additional measures and sound husbandry practices due to vaccines providing partial protection, especially in regions with elevated infection rates.